HeartSciences Showcases MyoVista® Wavelet ECG at 2018 Scientific Sessions of the American Heart Association (AHA)
HeartSciences , a medical device company developing next generation ECG devices using continuous wavelet transform (CWT) signal processing, is proud to announce its participation as an exhibitor at the upcoming 2018 Scientific Sessions of the American Heart Association (AHA). The AHA Congress will take place November 10-12, 2018 at the McCormick Place, Chicago, Illinois. HeartSciences will highlight its MyoVista® Wavelet ECG (wav ECG™) Cardiac Testing Device as well as recent clinical study results published in the Journal of the American College of Cardiology (JACC ).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181107005049/en/
The JACC article titled “Prediction of Abnormal Myocardial Relaxation from Signal Processed Surface ECG ” presented the results from the investigator-initiated clinical study that focused on evaluating the feasibility of MyoVista® Wavelet ECG as a diagnostic tool for predicting myocardial relaxation abnormalities. Results from the study demonstrate MyoVista’s patented technology based on CWT signal processing can detect myocardial relaxation abnormalities associated with LVDD.
HeartSciences is advancing the field of electrocardiography through the application of wavelet signal processing and artificial intelligence to develop next generation ECG technology. Wavelet signal processing is currently used in many different industries as an important tool to provide insights and new valuable data related to spectral analysis of a signal. HeartSciences’ MyoVista wav ECG Cardiac Testing Device is a 12-lead resting electrocardiograph utilizing continuous wavelet transform (CWT) based signal processing. Patented informatics focus on energy related information rather than conventional voltage-based information. HeartSciences mission is to enable accurate, affordable screening for the early detection of heart disease.
In addition to the proprietary informatics, the MyoVista wav ECG Device also features the capabilities of a full featured 12-lead resting ECG including analysis using the Glasgow Algorithm, one of the world’s most respected interpretive algorithms. The device has a 15.6-inch high-resolution touchscreen display and incorporates many features commonly associated with a tablet device requiring minimal user training as well as easy and intuitive use.
The MyoVista wav ECG Device is not currently approved for sale or distribution in the United States. The MyoVista Device is not FDA cleared.
HeartSciences is a privately-held U.S. corporation based in Southlake, Texas.
For more information visit www.heartsciences.com .
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
YOU-BANK18.6.2019 10:27:04 CEST | Pressemeddelelse
You Bank the Digital Asset Banking Platform Presents at UNCHAIN 2019 in Berlin
GA-ICONEX18.6.2019 10:02:20 CEST | Pressemeddelelse
Hansol Paper and Iconex Announce Mutual Decision to Withdraw from Agreement Governing Sale of Schades and R+S to Iconex
NY-NORSK-TITANIUM-AS18.6.2019 10:02:20 CEST | Pressemeddelelse
Norsk Titanium Marks Milestone in Additive Manufacturing
TEMENOS18.6.2019 10:02:10 CEST | Pressemeddelelse
Temenos Successfully Delivers a Single, State-of-the-Art Digital Platform for ABN AMRO’s Private and Corporate Banking Business
C5-CAPITAL18.6.2019 09:07:05 CEST | Pressemeddelelse
Onevinn Recognized as Finalist for 2019 Microsoft Security and Compliance Partner of the Year Award
TX-KCI18.6.2019 09:02:04 CEST | Pressemeddelelse
KCI Expands Surgical Portfolio in Europe
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.Besøg vores nyhedsrum